AUTHOR Nikesh Shukla hopes his new memoir will drive conversations on “the issues which keep him up at night”.
Brown Baby is addressed to his eldest child and details Shukla’s thoughts and experiences with racism, sexism, parenting as well as the pain of losing his mother. In an interview last week with Eastern Eye prior to the book’s release, the British Indian author said he wants the book’s contents to drive discussions on the “things that keep (him) up at night”.
“By presenting it as something that I’m thinking about, hopefully, other people will join me on that journey,” he said. “If we are all up at night thinking about the same stuff, maybe we can come together, work out how to fix stuff and sleep better.”
The memoir is written as a conversation with his daughter, known only as Ganga. Shukla said it was “really important to talk to her on topics (such as racism) in a way that makes sense to her.” “I wanted to write an ultimately optimistic book about how to prepare my kids for the way the world is,” he said. “I realised I put all of the things that scared me the most in the memoir and worked out ways of how I would talk to my daughters about them.”
He added: “I was asked recently, when do I want my daughters to read Brown Baby? And the more I thought about it, the more I thought, if I raise them properly, they won’t ever need to.”
Within Brown Baby, Shukla also depicts his mixed-race daughter’s experience with her own ethnicity. He tells a story of Ganga rejecting a doll with brown skin, describing its skin as “dirty”. On another occasion, Ganga informed her father that she wanted to be white, like her mother.
The father-of-two said his youngest daughter has not had the same conversations about her race and heritage as his eldest. He puts this down to the lesson learned with his first daughter. Now, he and his wife have active discussions with their children on their mixed-race ethnicity and encourage the idea of feeling “wholly brown, south Asian and wholly white British”.
“They are not half of anything, they are wholly both of those things, and that is okay,” he said. “It’s been quite empowering for them, because they don’t feel that lack that one might feel if they were only half of something.”
The memoir also explores Shukla’s relationship with his mother, who sadly passed away from lung cancer around the same time as the release of his first novel in 2010. He found writing about his memories of her death difficult, he said.
The chapters chronicling their time together and the aftermath of her death were “his way of grieving (for his mother) properly.” “I never really grieved for my mother at the time,” the London-born writer said. “My mum died and my novel came out all in the same fortnight so it was a very chaotic and destabilising time, and I just pushed myself towards promoting the book rather than dealing with my sadness.”
Brown Baby is addressed to Nikesh Shukla's eldest daughter, known only as 'Ganga'
Asked how his mother would react to Brown Baby, Shukla admitted she probably would not be happy with her portrayal within the book. “But I’d rather be honest, rather than have a romantic depiction of my mum,” he said.
A manifestation of the grief of losing his mum came in the form of binge-eating, a topic which Shukla does not shy away from. He writes about secretly eating junk-food in the dead of night, and lying to his wife about his food intake. Admitting it was a “really hard thing to write about”, Shukla believes the issues may have also stemmed from working on The Good Immigrant in 2016. The award-winning essay collection features a number of BAME contributors who explore otherness, racial inequality and the immigrant experience. Constantly thinking about racism triggered anxieties and stress which partly led to his compulsive snacking, he said.
“I always felt such shame about (my food issues),” he said. “I thought one way of dealing with it would be being very honest about it, but in being honest, I have to be prepared to talk about it and I forgot that bit. Once people know about it, they have questions about it and I hadn’t accounted for how hard that would be.”
The book also covers Shukla’s environmental concerns that may impact his daughters as they grow up, including climate catastrophe and the consequences of overpopulation. However, there’s no mention of the ongoing coronavirus crisis. Was he tempted to revise the chapter to share any feelings on the virus outbreak?
“No, I think it’s really hard to write about the pandemic, because we’re still living through it and everything is constantly changing,” the Bristol-based author explained. “I want to write reflectively, not reactively. That’s not the writing that I’m best at – I’ll leave that to others who are much better at writing about the world as it unfolds.”
Brown Baby: A Memoir of Race, Family and Home by Nikesh Shukla is out now
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.